MA50201A - Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants - Google Patents
Comprimés de défériprone à libération retardée et procédés d'utilisation correspondantsInfo
- Publication number
- MA50201A MA50201A MA050201A MA50201A MA50201A MA 50201 A MA50201 A MA 50201A MA 050201 A MA050201 A MA 050201A MA 50201 A MA50201 A MA 50201A MA 50201 A MA50201 A MA 50201A
- Authority
- MA
- Morocco
- Prior art keywords
- deferiprone
- delayed
- related methods
- release tablets
- tablets
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577055P | 2017-10-25 | 2017-10-25 | |
| US201762596043P | 2017-12-07 | 2017-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50201A true MA50201A (fr) | 2021-04-28 |
Family
ID=66170815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050201A MA50201A (fr) | 2017-10-25 | 2018-10-25 | Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants |
Country Status (17)
| Country | Link |
|---|---|
| US (8) | US10940116B2 (fr) |
| EP (1) | EP3684344A4 (fr) |
| JP (1) | JP7246384B2 (fr) |
| KR (1) | KR102624627B1 (fr) |
| CN (2) | CN114533689A (fr) |
| AU (1) | AU2018357350B2 (fr) |
| BR (1) | BR112020008128A2 (fr) |
| CA (2) | CA3077514C (fr) |
| IL (1) | IL273955A (fr) |
| MA (1) | MA50201A (fr) |
| MX (1) | MX2020004107A (fr) |
| NZ (1) | NZ763555A (fr) |
| PH (1) | PH12020550815A1 (fr) |
| SA (1) | SA520411808B1 (fr) |
| SG (1) | SG11202003153TA (fr) |
| UA (1) | UA126977C2 (fr) |
| WO (1) | WO2019082128A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020004107A (es) | 2017-10-25 | 2020-07-24 | Chiesi Farm Spa | Tabletas de deferiprona de liberacion retrasada y metodos de uso de las mismas. |
| US12016851B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| US12016850B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| WO2023198641A1 (fr) | 2022-04-11 | 2023-10-19 | Chiesi Farmaceutici S.P.A. | Formulations pharmaceutiques à libération modifiée comprenant de la défériprone |
| WO2023198640A1 (fr) | 2022-04-11 | 2023-10-19 | Chiesi Farmaceutici S.P.A. | Formulations pharmaceutiques à libération modifiée comprenant de la défériprone |
| WO2024079303A1 (fr) | 2022-10-14 | 2024-04-18 | Chiesi Farmaceutici S.P.A. | Formulations pharmaceutiques à libération modifiée comprenant de la défériprone |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI98343C (fi) * | 1995-03-21 | 1997-06-10 | Orion Yhtymae Oy | Peroraalinen formulaatio |
| US5747532A (en) | 1995-11-21 | 1998-05-05 | Medinox, Inc. | Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor |
| GB9625638D0 (en) | 1996-12-10 | 1997-01-29 | Cenes Ltd | Therapeutic antioxidants for alzheimer's diease |
| CA2733819A1 (fr) | 1999-12-30 | 2001-07-12 | Judith K. Gwathmey | Systeme de distribution de chelateur de fer |
| CA2313270C (fr) | 2000-06-30 | 2011-09-13 | Apotex Inc. | Utilisation de deferiprone pour le traitement et la prevention de maladies cardiaques induites par le fer |
| AU2003251920A1 (en) | 2002-07-12 | 2004-02-02 | The Buck Institute For Research On Aging | Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression |
| US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US8058442B2 (en) * | 2002-11-07 | 2011-11-15 | Technion Research And Development Foundation Ltd. | Neuroprotective iron chelators and pharmaceutical compositions comprising them |
| EP1776118A2 (fr) * | 2004-08-06 | 2007-04-25 | Shiva Biomedical, LLC | Chezateurs de fer pour le traitement du dysfonctionnement renal induit par les produits de contraste radiologique |
| GB0502475D0 (en) * | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
| NZ570730A (en) | 2006-02-22 | 2013-05-31 | The use of deferiprone and methods to treat and/or prevent Friedreich ataxia resulting from intracellular mishandling of iron | |
| MX2009002235A (es) | 2006-08-30 | 2009-03-13 | Jagotec Ag | Formulaciones de dosis oral, solidas, de liberacion controlada que comprenden nisoldipina. |
| US9744137B2 (en) | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| US20080138440A1 (en) * | 2006-11-29 | 2008-06-12 | Cormedix Inc. | Methods of diagnosing and alleviating gadolinium toxicity |
| CN101352438A (zh) | 2007-07-25 | 2009-01-28 | 复旦大学 | 去铁酮及其制剂在制备防治蒽环类药物心脏毒性药物中的用途 |
| UA102254C2 (ru) | 2008-04-25 | 2013-06-25 | Апотекс Технолоджис Инк. | Жидкий состав для деферипрона с приятным вкусом |
| WO2009155088A1 (fr) | 2008-05-30 | 2009-12-23 | University Of Cincinnati | Inhibition de la formation de biofilms à l'aide de chélateurs de zinc |
| WO2010005851A1 (fr) | 2008-07-08 | 2010-01-14 | Xenon Pharmaceuticals Inc. | Polythérapie destinée au traitement de troubles du fer |
| US20100255082A1 (en) * | 2008-07-31 | 2010-10-07 | Ishwar Chauhan | Functionally Coated Breakable Tablets |
| EP2206506A1 (fr) | 2008-12-18 | 2010-07-14 | Bracco Imaging S.p.A | Formulations probiotiques |
| EA201170970A1 (ru) | 2009-01-26 | 2012-03-30 | Майкл Спино | Применение деферипрона для лечения и предупреждения заболеваний глаз, связанных с железом |
| US8603814B2 (en) | 2009-07-20 | 2013-12-10 | Rutgers The State University Of New Jersey | Method of inhibiting nonsense-mediated mRNA decay |
| US20120172292A1 (en) | 2009-09-10 | 2012-07-05 | New York University | Method for protection of antimicrobial and anticancer drugs from inactivation by nitric oxide |
| US8563035B2 (en) * | 2010-05-05 | 2013-10-22 | Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi | Oral tablet compositions of dexlansoprazole |
| CN103476419A (zh) * | 2011-01-07 | 2013-12-25 | 梅里翁第三研究有限公司 | 口服投药的含铁药物组合物 |
| DE102011112898A1 (de) | 2011-09-08 | 2013-03-14 | Charité - Universitätsmedizin Berlin | Nanopartikuläres Phosphatadsorbens basierend auf Maghämit oder Maghämit/Magnetit, dessen Herstellung und Verwendungen |
| JP2014533697A (ja) | 2011-11-18 | 2014-12-15 | アポテックス テクノロジーズ インコーポレイテッドＡｐｏｔｅｘ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | デフェリプロンを用いた処置方法 |
| WO2013139931A1 (fr) | 2012-03-21 | 2013-09-26 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Composition destinée à être utilisée dans le traitement de maladies neurodégénératives ayant des syndromes parkinsoniens |
| AU2013343250A1 (en) * | 2012-11-12 | 2015-04-09 | Cipla Limited | Fixed dose pharmaceutical composition comprising deferasirox and deferipone |
| MX2015015553A (es) | 2013-05-10 | 2016-06-17 | Cipla Ltd | Composicion farmceutica de dosis baja. |
| ES2895044T3 (es) | 2013-06-06 | 2022-02-17 | Albion Laboratories Inc | Suplemento de hierro |
| ITMI20132066A1 (it) * | 2013-12-11 | 2015-06-12 | Farmatron Ltd | Sistemi terapeutici a rilascio modificato per la somministrazione orale di mentolo nel trattamento delle malattie intestinali |
| AU2017307566B2 (en) | 2016-08-05 | 2023-06-15 | Abfero Pharmaceuticals, Inc. | Dosing regimens for treating metal-mediated conditions |
| US20180362228A1 (en) * | 2017-02-16 | 2018-12-20 | Jeffrey D. Jacobson | Container closure with integrated utensil |
| MX2020004107A (es) | 2017-10-25 | 2020-07-24 | Chiesi Farm Spa | Tabletas de deferiprona de liberacion retrasada y metodos de uso de las mismas. |
-
2018
- 2018-10-25 MX MX2020004107A patent/MX2020004107A/es unknown
- 2018-10-25 JP JP2020523267A patent/JP7246384B2/ja active Active
- 2018-10-25 CA CA3077514A patent/CA3077514C/fr not_active Expired - Fee Related
- 2018-10-25 UA UAA202003078A patent/UA126977C2/uk unknown
- 2018-10-25 CA CA3172668A patent/CA3172668A1/fr not_active Withdrawn
- 2018-10-25 WO PCT/IB2018/058350 patent/WO2019082128A1/fr active Application Filing
- 2018-10-25 CN CN202210164525.3A patent/CN114533689A/zh active Pending
- 2018-10-25 KR KR1020207014502A patent/KR102624627B1/ko active IP Right Grant
- 2018-10-25 MA MA050201A patent/MA50201A/fr unknown
- 2018-10-25 EP EP18871663.3A patent/EP3684344A4/fr active Pending
- 2018-10-25 US US16/171,170 patent/US10940116B2/en active Active
- 2018-10-25 NZ NZ763555A patent/NZ763555A/en unknown
- 2018-10-25 AU AU2018357350A patent/AU2018357350B2/en active Active
- 2018-10-25 CN CN201880069331.7A patent/CN111918646B/zh active Active
- 2018-10-25 US US16/759,254 patent/US20200253945A1/en not_active Abandoned
- 2018-10-25 US US16/171,173 patent/US10780055B2/en active Active
- 2018-10-25 BR BR112020008128-0A patent/BR112020008128A2/pt unknown
- 2018-10-25 SG SG11202003153TA patent/SG11202003153TA/en unknown
-
2019
- 2019-12-13 US US16/714,520 patent/US11458103B2/en active Active
-
2020
- 2020-04-03 US US16/839,928 patent/US11357731B2/en active Active
- 2020-04-13 IL IL273955A patent/IL273955A/en unknown
- 2020-04-20 PH PH12020550815A patent/PH12020550815A1/en unknown
- 2020-04-21 SA SA520411808A patent/SA520411808B1/ar unknown
- 2020-05-12 US US15/930,373 patent/US10940115B2/en active Active
-
2021
- 2021-05-21 US US17/327,135 patent/US11723874B2/en active Active
-
2022
- 2022-05-12 US US17/742,960 patent/US11607389B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50201A (fr) | Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants | |
| MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
| MA50077A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA48772A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA45280A (fr) | Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation | |
| MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
| MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
| MA43802A (fr) | Matières cellulosiques et procédés de fabrication et d'utilisation de celles-ci | |
| MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
| MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
| MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
| MA44990A (fr) | Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1 | |
| MA47499A (fr) | Anticorps anti-tau et leurs procédés d'utilisation | |
| MA50636A (fr) | Compositions et procédés pour inhiber l'activité d'arginase | |
| MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
| MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci | |
| MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA54851A (fr) | Oxystérols et leurs procédés d'utilisation |